Picture of Amylyx Pharmaceuticals logo

AMLX Amylyx Pharmaceuticals Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapNeutral

Momentum

Relative Strength (%)
1m+42.85%
3m+75.77%
6m+7.72%
1yr-86.85%
Volume Change (%)
10d/3m-21.54%
Price vs... (%)
52w High-84.36%
50d MA+29.3%
200d MA-47.58%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-67.83%
Return on Equity-51.22%
Operating Margin-59.5%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Amylyx Pharmaceuticals EPS forecast chart

Profile Summary

Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery and development of treatments for neurodegenerative diseases. The Company is focused on the development and commercialization of its product candidate: AMX0035 for the treatment of Wolfram syndrome and for the treatment of progressive supranuclear palsy, and AMX0114, the Company’s antisense oligonucleotide targeting calpain-2 for the treatment of amyotrophic lateral sclerosis (ALS). AMX0035 is a dual-unfolded protein response (UPR)-Bax apoptosis inhibitor composed of PB and TURSO (also known as TUDCA). The Company’s Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist that has been evaluated in five clinical trials for post-bariatric hypoglycemia (PBH) and has also been studied in congenital hyperinsulinism (HI), two indications characterized by hyperinsulinemic hypoglycemia.

Directors

    Last Annual
    December 31st, 2023
    Last Interim
    June 30th, 2024
    Incorporated
    January 10th, 2014
    Public Since
    January 7th, 2022
    No. of Shareholders
    21
    No. of Employees
    384
    Sector
    Pharmaceuticals
    Industry
    Healthcare
    Exchange
    us flag iconNASDAQ Global Select Market
    Shares in Issue
    68,082,468

    AMLX Share Price Performance

    Upcoming Events for AMLX

    Similar to AMLX

    Picture of Amgen logo

    Amgen

    us flag iconNASDAQ Global Select Market

    Picture of Amneal Pharmaceuticals logo

    Amneal Pharmaceuticals

    us flag iconNASDAQ Global Select Market

    Picture of Amphastar Pharmaceuticals logo

    Amphastar Pharmaceuticals

    us flag iconNASDAQ Global Select Market

    Picture of Apellis Pharmaceuticals logo

    Apellis Pharmaceuticals

    us flag iconNASDAQ Global Select Market

    Picture of AstraZeneca logo

    AstraZeneca

    us flag iconNASDAQ Global Select Market

    FAQ